News

The shape of molecules to come

A Q&A on designing DNA nanostructures for biomedical applications
Erin Frick
By Erin Frick
Oct. 26, 2024

By discovering new ways to manipulate matter at the atomic and molecular levels, advances in nanotechnology are paving the way for innovations in medicine, electronics, materials science and environmental remediation, among many other areas. An important specialty in this field — and a signature area of study at the University at Albany’s RNA Institute — is DNA nanotechnology, wherein the base pairs that comprise DNA molecules are manipulated to build tiny structures in different shapes that can be used for applications including drug delivery, medical diagnostics and even data storage. 

Members of the Chandrasekaran lab coauthored a new paper on switchback DNA. Left to right: Arun Richard Chandrasekaran, Bharath Raj Madhanagopal, undergraduate researcher Hannah Talbot, research associate Arlin Rodriguez
Members of the Chandrasekaran lab coauthored a new paper on switchback DNA. Left to right: Arun Richard Chandrasekaran, Bharath Raj Madhanagopal, undergraduate researcher Hannah Talbot, research associate Arlin Rodriguez.

RNA Institute researchers including postdoctoral fellow Bharath Raj Madhanagopal and senior research scientist Arun Richard Chandrasekaran, together with a team of UAlbany collaborators, coauthored a new study that explored the unique properties of a certain kind of DNA nanostructure called “switchback DNA” that could have implications for DNA folding in nature and be useful in designing new types of nanostructures with biomedical applications. 

Their findings were published in Nature Communications.

Madhanagopal and Chandrasekaran shared insights on the fundamentals of their field and the advances that lie in wait with new discoveries in DNA nanotechnology.

What are DNA nanostructures and why are they important?

Many know DNA as the molecule that stores the genetic information that is passed from one generation to the next. The chemical properties of DNA that make it an excellent molecule for storing genetic information also make it a useful construction material — especially when it comes to making tiny objects, as small as a few nanometers. 

The sequences of the four nucleobases in DNA — adenine, guanine, thymine and cytosine — are inherently programmable. This is because adenine always pairs with thymine, and guanine with cytosine. These reliable patterns in base pairing allow us to design specific strands of DNA that bind together like Lego blocks to form nanostructures.

By using DNA to build nanostructures, we can achieve excellent precision in the size of the structures. We can also make objects of diverse shapes and architectural intricacies — capabilities that are not easily achieved using other technologies. DNA nanostructures are now being developed for use in drug delivery, diagnostics, and data storage, to name a few applications.  

What is ‘switchback DNA’? 

Just as we use bricks to construct buildings, we use nanometer-sized building blocks called “motifs” and “tiles” made of DNA to create elaborate structures in DNA nanotechnology. Similar to how bricks can come in different shapes and sizes, so can motifs and tiles. Creating these structural motifs and understanding their properties is the foundation of DNA nanotechnology research. 

“Switchback DNA” is one of the earliest DNA motifs designed by Nadrian Seeman, the founder of the field of DNA nanotechnology. We wanted to explore how its curious structural features would manifest in nanostructures. By studying the properties of switchback DNA, we believe we can create even more diverse DNA-based nano-objects with exotic properties. 

What makes switchback DNA unique? 

Switchback DNA has only two strands, so it can be directly compared with the double helical structure of DNA that everyone is familiar with. In switchback DNA, the two strands have sections, called half-turns, that resemble normal DNA, but the way they are arranged makes switchback DNA unique. 

Typically, DNA is a double helix with right-handed helical sense throughout the molecule. In switchback DNA, right-handed half-turns are arranged in such a way that the molecule as a whole is a left-handed double helix. This is because if you trace the backbone of DNA along the helix, you will find that after every half-turn, the strands fold back. These differences are illustrated in the diagram below. 

We have found that switchback DNA’s unique structure can affect properties important to its potential role in biomedical applications — things like structural stability, vulnerability to enzymes, and immunogenic properties, which, for example, can impact the ability of a nanostructure to effectively deliver a drug to a particular tissue. Understanding these properties, and figuring out which can be controlled and how to control them, is critical. 

Switchback DNA is made up of structural sections called “half-turns” that resemble normal DNA but are arranged differently. This diagram demonstrates these structural differences, which give switchback DNA its unique ability to fold, among other distinct properties.
Switchback DNA is made up of structural sections called “half-turns” that resemble normal DNA but are arranged differently. This diagram demonstrates these structural differences, which give switchback DNA its unique ability to fold, among other distinct properties.

What does the field stand to gain by better understanding switchback DNA?

The results of this study will help researchers who make DNA nanostructures improve their designs using switchback DNA building blocks. 

For example, we now know that a common enzyme called “DNase I” does not degrade switchback DNA as quickly as it degrades conventional B-DNA (the DNA that is generally found in living organisms). If we want to use DNA nanostructures to carry drugs to tissues in the body, we don’t want an enzyme to break down the nanostructure before it can reach the target tissue. If this happened, the drug would not be effective. We can now consider incorporating switchback DNA to help mitigate this challenge, which is a common roadblock in the field. 

We also found that there are genetic sequences in the human genome that can potentially fold into switchback DNA. Our results suggest that under some conditions, DNA with specific repeating patterns could form switchback DNA. These sequences are prevalent in the chromosomes of animals and plants, and can adopt structural forms about which we know very little. It is exciting to know that these sequences can fold into switchback DNA in a test tube under certain conditions. Whether this can happen in a living cell remains to be seen. 

Because these repetitive sequences are involved in diseases such as myotonic dystrophy and Huntington’s disease, this avenue of study may help us better understand this class of diseases, and it may also help us discover new drug targets for these diseases in the future. 

What are the biggest takeaways from this work? 

Our work with switchback DNA shows that we can "tune" the properties of DNA by folding it into different patterns without chemical modifications. Understanding properties of switchback DNA will be useful in creating DNA devices for biosensing, drug delivery, DNA computation and other applications. 

Our findings also demonstrate that the rules of complementarity that Watson and Crick defined in their iconic double-helical model of DNA structure need to be expanded. In the model proposed by Watson and Crick, the direction of the two strands are opposite. That means one end of the first strand interacts with the opposite end of the second strand. In switchback DNA, the base pairing pattern is different. While most of the rules of complementarity defined by Watson and Crick apply to switchback DNA, the position of the base pairs differs. 

Finally, our hypothesis that repeat sequences could form switchback DNA structures opens up interesting discussions — and future studies — on the biological occurrence of such non-traditional DNA structures.

This article is republished from the University at Albany News Center. Read the original here.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Erin Frick
Erin Frick

Erin Frick is a communications specialist at the University at Albany covering health and life sciences.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Guiding grocery carts to shape healthy habits
Award

Guiding grocery carts to shape healthy habits

Nov. 21, 2024

Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Quantifying how proteins in microbe and host interact
Journal News

Quantifying how proteins in microbe and host interact

Nov. 20, 2024

“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.

Leading the charge for gender equity
Award

Leading the charge for gender equity

Nov. 19, 2024

Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

CRISPR gene editing: Moving closer to home
News

CRISPR gene editing: Moving closer to home

Nov. 17, 2024

With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.

Finding a missing piece for neurodegenerative disease research
News

Finding a missing piece for neurodegenerative disease research

Nov. 16, 2024

Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.

From the journals: JLR
Journal News

From the journals: JLR

Nov. 15, 2024

Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.